VEGFA and neoplasm: Judah Folkman’s vision of targeting the tumor neovasculature as a new modality of cancer therapeutics has inspired a series of drugs that either exclusively (e.g., bevacizumab) or primarily (e.g., sunitinib, axitinib, and sorafenib) inhibit VEGF signaling (McIntyre and Harris, 2015, Vasudev and Reynolds, 2014; and references therein) with associated beneficial responses, representing proof of principle and new additions to the armamentarium of anti-cancer drugs.